Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public











Title  Creator  Group name  Publishing year 
Harnessing Fc/FcRn Affinity Data from Patents with Different Machine Learning Methods Dumet et al. PlateformePP2I 2023-03-16
10th antibody industrial symposium: new developments in antibody and adoptive cell therapies Antunes et al. EquipePM 2023
4C3 Human Monoclonal Antibody: A Proof of Concept for Non-pathogenic Proteinase 3 Anti-neutrophil Cytoplasmic Antibodies in Granulomatosis With Polyangiitis Granel et al. PlateformePP2I 2020
[Players from the program "Investments for the Future": MAbImprove MabEx] Larivière et al. EquipeAP Dec 2019
[A word from the coordinators] Pèlegrin et al. EquipeAP Dec 2019
Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France Martineau et al. EquipeAT May 01, 2019
Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France Martin et al. EquipeAP 2018 Feb/Mar
IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding Ternant et al. PlateformePP2I Jan 15, 2016


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés